Artiva Biotherapeutics, Inc. ARTV Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 8.2×-5.8× | 8.6×— | 11.6×— | 13.8×— | 13.9×— | |
| Leverage | ||||||
| Debt-to-equity | 0.1×— | 0.1×— | 0.1×— | 0.1×— | —— | |
| Per Share | ||||||
| Book value per share | $3.56-48.7% | $4.50-72.9% | $5.28-50.4% | $6.11+103% | $6.93+103% | |
| Valuation | ||||||
| Market capitalization | $429.03M+1,015% | $105.3M— | $70.1M— | —— | —— | |
| Price / book | 4.9×+4.7× | 1×— | 0.5×— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Artiva Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Artiva Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.